Cell cycle arrest induced by the vitamin D3 analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27

Experimental Cell Research

Volumn 254, Issue 2, 2000, Pages 279-286

  Park, Woo Hyun ^a,c   Seol, Jae Goo ^a   Kim, Eun Shil ^a   Jung, Chul Won ^b   Lee, Chung Choo ^c   Binderup, Lise ^d   Koeffler, H Phillip ^e   Kim, Byoung Kook ^a   Lee, Young Yiul ^f  

^a Seoul National University College of Medicine   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d LEO PHARMA A S   (Denmark)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Hanyang University   (South Korea)

Author keywords

Cell cycle; Cyclin dependent kinase inhibitor; Myeloma; p27; Vitamin D3 analog

Indexed keywords

COLECALCIFEROL DERIVATIVE; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN P27; SEOCALCITOL; VITAMIN D RECEPTOR;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; RECEPTOR DENSITY; TUMOR CELL LINE;

EID: 0009634071     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4735     Document Type: Article

References (49)

1. Reichel H., Koeffler H. P., Norman A. W. The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med. 320:1990;980-991.
2. 3 receptors: Gene regulation and genetic circuitry. FASEB J. 2:1988;3043-3053.
3. 3. J. Nutr. 125:1995;1690S-1694S.
4. Niles R. M. Use of vitamin A and D in chemoprevention and therapy of cancer: Control of nuclear receptor expression and function. Vitamins, cancer and receptors. Adv. Exp. Med. Biol. 375:1995;1-15.
5. 3-induced differentiation in a human myeloid leukemia cell line (HL-60): Receptor-mediated maturation to macrophage-like cells. J. Cell. Biol. 76:1985;1-6.
6. 3 receptor mediated modulation of the human myeloma cell line RPMI 8226. Cancer Res. 48:1988;1213-1216.
7. 3 receptors in human leukocytes. Science. 221:1983;1181-1183.
8. 3 on primary cultures of human prostatic cells. Cancer Res. 54:1994;805-810.
9. 3. Endocrinology. 136:1995;20-26.
10. Danielpour D., Kadomatsu K., Anzano M. A., Smith J. M., Sporn M. B. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res. 54:1994;3413-3421.
11. 3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J. Cell. Biochem. 66:1997;413-425.
12. Eisman J. K., Martin T. J., MacIntyre I., Moseley J. M. 1,25-Dihydroxy-vitamin-D receptor in breast cancer cells. Lancet. 2:1979;1335-1336.
13. Framptom R. J., Omond S. A., Eisman J. A. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin-D metabolites. Cancer Res. 43:1983;443-447.
14. Colston K. W., Chander S. K., MacKay A. G., Coombes R. C. Effects of synthetic vitamin D analogs on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol. 44:1992;693-702.
15. Bower M., Colston K. W., Stein R. C., Hedley A., Gazet J-C., Ford H. T., Coombes R. C. Topical calcipotriol treatment in advanced breast cancer. Lancet. 337:1991;701-702.
16. 3 on the morphology of human breast cancer cell line BT-20. Differentiation. 40:1989;63-69.
17. 3: Towards an endocrine therapy of brain tumors. J. Neurosci. Res. 37:1994;271-277.
18. 3, inhibits azoxymethane-induced colonic tumorgenesis. Cancer Res. 55:1995;3050-3054.
19. 3. Cancer Res. 54:1994;4057-4064.
20. Yu J., Papavasiliou V., Rhim J., Goltzman D., Kremer R. Vitamin D analogs: New therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs. 6:1995;101-108.
21. 3. Proc. Natl. Acad. Sci. USA. 78:1981;4990-4994.
22. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc. Natl. Acad. Sci. USA. 80:1983;201-204.
23. 3 prolongs survival time of leukemic mice. Proc. Natl. Acad. Sci. USA. 87:1990;3929-3932.
24. 3: Differential effects on leukemic cell growth, differentiation, and intestinal absorption. Cancer Res. 50:1990;6857-6864.
25. Sherr C. J. Cancer cell cycle. Science. 274:1996;1672-1677.
26. Morgan D. O. Principal of CDK regulation. Nature. 374:1995;131-134.
27. Jeffrey P. D., Russo A. A., Polyak K., Gibbs E., Hurwitz J., Massague J., Pavletich N. P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 376:1995;313-320.
28. Dynlacht B. D. Regulation of transcription by proteins that control the cell cycle. Nature. 389:1997;149-152.
29. 3 in HL60 cells. Cancer Res. 56:1996;264-267.
30. Wang Q. M., Luo X., Studzinski G. P. Cyclin-dependent kinase 6 is the principal target of p27/Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells. Cancer Res. 57:1997;2851-2855.
31. Puthier D., Bataille R., Barille S., Mellerin M-P., Harousseau J-L., Ponzio A., Robillard N., Wijdenes J., Amoit M. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Blood. 88:1996;4659-4666.
32. Kawa S., Nikaido T., Aoki Y., Zhai Y., Kumagai T., Furihata K., Fujii S., Kiyosawa K. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br. J. Cancer. 76:1997;884-889.
33. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10:1996;142-153.
34. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
35. Peter M., Herskowitz I. Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell. 79:1994;181-184.
36. Elledge S. J., Harper J. W. Cdk inhibitors: On the threshold of checkpoints and development. Curr. Opin. Cell Biol. 6:1994;847-852.
37. Brugarolas J., Chandrasekaran C., Gordon J. I., Beach D., Jacks T., Hannon G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377:1995;552-557.
38. 3 and its analogue, EB1089, in human breast cells. Oncogene. 15:1997;1555-1563.
39. 3 analog, EB1089, on hematopoietic stem cells from normal and myeloid leukemic blasts. Leukemia. 10:1996;1751-1757.
40. Colston K. W., Mackey A. G., James S. Y., Binderup L., Chander S., Coombes R. C. A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 44:1992;2273-2280.
41. Powell B. L., Gregory B. W., Kute T. E., Morgan T. M., Lyerly E. S., Capizzi R. L. Bromodeoxyuridine incorporation into DNA of human leukemia cells is not concentration dependent. Cytometry. 11:1990;438-441.
42. 3 analogs: A unique class of potent inhibition of proliferation of prostate, breast, and hemotopoietic cancer cells. Cancer Res. 58:1998;3370-3375.
43. Pakkala I., Savli H., Knuutila S., Binderup L., Pakkala S. CB1093, a novel vitamin D analog: Effects on differentiation and clonal growth on HL-60 and de novo leukemia cells. Leukemia Res. 21:1997;321-3226.
44. Zhuang S-H., Schwartz G. G., Cameron D., Burnstein K. L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol. Cell. Endocrinology. 126:1997;83-90.
45. 3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res. 1:1995;997-1003.
46. 3 receptors and actions in human prostate cancer cell lines. Endocrinology. 132:1993;1952-1960.
47. Stiegler P., De Luca A., Bagella L., Giordano A. The COOH-terminal region of pRb/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter. Cancer Res. 58:1998;5049-5052.
48. Liu N., Lucibello F. C., Engeland K., Muller R. A. New model of cell cycle-regulated transcription: Repression of the cyclin A promoter by CDF-1 and anti-repression by E2F. Oncogene. 16:1998;2957-2963.
49. Spitkovsky D., Schulze A., Boye B., Jansen-Durr P. Down-regulation of cyclin A gene expression upon genotoxic stress correlates with reduced binding of free E2F to the promoter. Cell Growth Differ. 8:1997;699-710.